REFERENCES
- Meyer MC. Drug Product Selection. Part 2. Scientific Basis of Bioavailability and Bioequivalence Testing. Am Pharm. 1991; N531: 47–52
- Molzon JA. The Generic Drug Approval Process. J Pharm Law 1996; 5: 275–284
- Connor DP, Davit BM. Generic Drug Product Development: Solid Oral Dosage Forms, Shargel Leon, Kanfer Isadore. Marcel Dekker Inc. 2004
- Schuirmann DJ. A comparison of the two one-sided test procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokin Biopharm. 1987; 15: 657–680, [CROSSREF]
- Tothfalusi L, Endrenyi L, Midha KK. Scaling or wider bioequivalence limits for highly-variable drugs and for the special case of Cmax. Int J Clin Pharmacol Ther 2003; 41: 217–225, [PUBMED], [INFOTRIEVE]
- Tothfalusi L, Endrenyi L. Limits for the scaled average bioequivalence of highly-variable drugs and drug products. Pharm Res 2003; 20(3)382–389, [PUBMED], [INFOTRIEVE], [CROSSREF]
- http://www.fda.gov/cder/ob/default.htm, Approved Drug Products with Therapeutics Equivalence Evaluations, 21st Edition, Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Information Technology, Division of Data Management and Services (2001)